PMO Interview with the Innovator Series: Volume 2
Peter Hirth, PhD
Video Categories: PMO Interview with the Innovator Series
The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
Jayson Slotnik provides an overview of the issues in demonstrating the value of personalized medicine tests and products
Dr. Jorge Cortes provides examples of how personalized or precision medicine has positively impacted the approach to cancer care, citing the benefits of FLT3 inhibitors, IDH inhibitors, and MEK inhibitors, and other targeted treatments.